ConductScience.org, home

Paper24254965

Hydroxychloroquine is a good second-line treatment for adults with immune thrombocytopenia and positive antinuclear antibodies.

Khellaf M and 8 others. Am J Hematol, 2014. Cited by 49 papers, by iCite.

Cite this record

ConductScience Library. Hydroxychloroquine is a good second-line treatment for adults with immune thrombocytopenia and positive antinuclear antibodies. Papers, record 24254965. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/24254965

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Hydroxychloroquine is a good second-line treatment for adults with immune thrombocytopenia and positive antinuclear antibodies.
PubMed
Journal
Am J Hematol
PubMed
Year
2014
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
49
iCite
Relative citation ratio, by iCite
2
iCite
Revised in PubMed
2014-02-17
PubMed

Authors9

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Khellaf MMehdi
2Chabrol AAmèlie
3Mahevas MMatthieu
4Roudot-Thoraval FFrançoise
5Limal NNicolas
6Languille LLaetitia
7Bierling PPhilippe
8Michel MMarc
9Godeau BBertrand

Source PubMed

Download CSV of authors

Topics13

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antibodies, AntinuclearMajor topic
Antirheumatic AgentsMajor topic
HydroxychloroquineMajor topic
Purpura, Thrombocytopenic, IdiopathicMajor topic
Adolescent
Adult
Female
Humans
Lupus Erythematosus, Systemic
Male
Middle Aged
Treatment Outcome
Young Adult

Source PubMed

Download CSV of topics

Trials6

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's recordSource
NCT01549184Retrospective Analysis of the Safety and Efficacy of Hydroxychloroquine in Immune ThrombocytopeniaDerived from the trialYesClinicalTrials.gov
NCT02444728Cyclophosphamide and Hydroxychloroquine for Thrombocytopenia in SLEResultsClinicalTrials.gov
NCT03229746Reposition of Second Line Treatment in Chronic Immune ThrombocytopeniaResultsClinicalTrials.gov
NCT06479291The Efficacy and Safety of HCQ Plus TPO-RA in ANA Positive ITPResultsClinicalTrials.gov
NCT06479304The Efficacy and Safety of HCQ Plus Pred in ANA Positive ITPResultsClinicalTrials.gov
NCT06479317The Efficacy and Safety of HCQ Plus DEX in ANA Positive ITPResultsClinicalTrials.gov

Download CSV of trials

Cited by23

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 49 citations.

PMIDTitleJournalYearIn PapersSource
42603197Antinuclear antibody titre and its dynamics predict autoimmune disease progression in adults with immune thrombocytopenia.Clin Rheumatol2026https://conductscience.org/library/papers/42603197PubMed
42266695Autophagy, NET formation, and inflammation crosstalk in thrombotic autoimmune diseases.Front Immunol2026https://conductscience.org/library/papers/42266695PubMed
41585259
Comparison of the efficacy of thalidomide combined with low-dose rituximab and low-dose rituximab alone in the treatment of steroid-resistant/refractory adult patients with primary immune thrombocytopenia: an open-label trial.
Front Med (Lausanne)2025https://conductscience.org/library/papers/41585259PubMed
41569352Immune thrombocytopenia in patients with connective tissue disease.Clin Rheumatol2026https://conductscience.org/library/papers/41569352PubMed
41495809A study of clinical manifestations and associated factors in photosensitive patients with systemic lupus erythematosus.Eur J Med Res2026https://conductscience.org/library/papers/41495809PubMed
39719150Primary versus Secondary Immune Thrombocytopenia (ITP): A Meeting Report from the 2023 McMaster ITP Summit.Thromb Haemost2025https://conductscience.org/library/papers/39719150PubMed
39627479Immune thrombocytopenia in patients with systemic lupus erythematosus.Clin Rheumatol2025https://conductscience.org/library/papers/39627479PubMed
39374586Sustained remission at long term follow-up in adolescents and young adults with chronic primary immune thrombocytopenia.Blood Adv2024https://conductscience.org/library/papers/39374586PubMed
38916764Description of therapeutic strategies in severe systemic lupus erythematosus-associated immune thrombocytopenia: a retrospective cohort study of response and relapse.Clin Rheumatol2024https://conductscience.org/library/papers/38916764PubMed
36969501Risk factors of significant relapse and appropriate maintenance therapy strategy in SLE-associated immune thrombocytopenia.Ther Adv Chronic Dis2023https://conductscience.org/library/papers/36969501PubMed
36658588How we treat primary immune thrombocytopenia in adults.J Hematol Oncol2023https://conductscience.org/library/papers/36658588PubMed
35708136Diagnosis of immune thrombocytopenia, including secondary forms, and selection of second-line treatment.Haematologica2022https://conductscience.org/library/papers/35708136PubMed
35401500Sirolimus Monotherapy for Thrombocytopenia in Primary Antiphospholipid Syndrome: A Pilot Study From a Tertiary Referral Center.Front Immunol2022https://conductscience.org/library/papers/35401500PubMed
34628650Consensus guidelines for the management of adult immune thrombocytopenia in Australia and New Zealand.Med J Aust2022https://conductscience.org/library/papers/34628650PubMed
34572358Immune Thrombocytopenia in Antiphospholipid Syndrome: Is It Primary or Secondary?Biomedicines2021https://conductscience.org/library/papers/34572358PubMed
33801294Emerging Therapies in Immune Thrombocytopenia.J Clin Med2021https://conductscience.org/library/papers/33801294PubMed
32384539Significance of antinuclear antibodies in primary immune thrombocytopenia: results of the CARMEN registry.Blood Adv2020https://conductscience.org/library/papers/32384539PubMed
32185250Lupus thrombocytopenia: pathogenesis and therapeutic implications.Mediterr J Rheumatol2017https://conductscience.org/library/papers/32185250PubMed
32135622[Interpretation of the updated international consensus report on the investigation and management of adult primary immune thrombocytopenia (version 2019)].Zhonghua Xue Ye Xue Za Zhi2020https://conductscience.org/library/papers/32135622PubMed
31770441Updated international consensus report on the investigation and management of primary immune thrombocytopenia.Blood Adv2019https://conductscience.org/library/papers/31770441PubMed

See all 23 cited byDownload CSV of cited by

Drugs8

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targetsSource
CYCLOPHOSPHAMIDECHEMBL1200796Results1https://conductscience.org/library/drugs/CHEMBL1200796ChEMBL
HYDROXYCHLOROQUINECHEMBL1535Results5https://conductscience.org/library/drugs/CHEMBL1535ChEMBL
AZATHIOPRINECHEMBL1542Results2https://conductscience.org/library/drugs/CHEMBL1542ChEMBL
DEXAMETHASONECHEMBL384467Results1https://conductscience.org/library/drugs/CHEMBL384467ChEMBL
ELTROMBOPAGCHEMBL461101Results1https://conductscience.org/library/drugs/CHEMBL461101ChEMBL
PREDNISONECHEMBL635Results1https://conductscience.org/library/drugs/CHEMBL635ChEMBL
METHYLPREDNISOLONECHEMBL650Results1https://conductscience.org/library/drugs/CHEMBL650ChEMBL
VINCRISTINECHEMBL90555Results1https://conductscience.org/library/drugs/CHEMBL90555ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • References
  • Genes
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/24254965

GET https://conductscience.org/api/papers/v1/24254965/cited_by?page=2